Northwest Biotherapeutics (NWBO) EBT Margin (2010 - 2026)

Northwest Biotherapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 2681.38% for Q1 2026.

• In Q1 2026, EBT Margin rose 236209.0% year-over-year to 2681.38%; the TTM figure through Mar 2026 stood at 4747.03% (down 10969.0% YoY), while the FY2025 annual figure was 4404.86%, up 165722.0% from the prior year.
• EBT Margin for Q1 2026 stood at 2681.38%, down from 2399.7% in the prior quarter.
• The five-year high for EBT Margin was 1589.89% in Q1 2023, with the low at 63220.87% in Q3 2022.
• The 5-year median for EBT Margin is 4723.48% (2022), against an average of 8695.21%.
• The sharpest annual moves came in 2022 and 2023: EBT Margin sank 5989145 bps in 2022, then surged 5939698 bps in 2023.
• Northwest Biotherapeutics' EBT Margin stood at 3189.11% in 2022, then gained by 21 bps to 2516.18% in 2023, then plunged by 130 bps to 5779.22% in 2024, then jumped by 58 bps to 2399.7% in 2025, then dropped by 12 bps to 2681.38% in 2026.
• Business Quant data shows NWBO's EBT Margin at 2681.38% in Q1 2026, 2399.7% in Q4 2025, and 8470.5% in Q3 2025.